In agreement with our findings, it was recently reported that a new mTOR kinase inhibitor, WYE‐687, increased apoptosis and blocked activation of both mTORC1 and mTORC2 through the feedback activation of p‐Akt in RCC cells, and oral administration of WYE‐687 potently suppressed tumor growth in nude mice injected with 786‐O cells (Pan et al., 2017). This evidence concerns the gene AKT1 and renal cell adenocarcinoma.